
STERIS (STE) Stock Forecast & Price Target
STERIS (STE) Analyst Ratings
Bulls say
Steris is well-positioned for future growth with strong organic revenue growth, consistent margin expansion, and supportive capital allocation strategies. The company's focus on healthcare services and biopharma manufacturing, as well as its global leadership in contract sterilization, make it a reliable and essential player in the medical technology industry. Additionally, the company's recent complementary acquisitions and plans for new facilities and a share buyback program demonstrate a commitment to long-term growth and shareholder value.
Bears say
Steris is a global leader in contract sterilization services, but recent trends in healthcare spending and potential regulatory actions from the FDA may impede the company's stock performance. The company is making a significant investment in a new facility in North Carolina, but the benefits of this investment may not be seen for multiple years. There are also several factors impacting operating margin trends, including potential cost increases related to energy and raw materials, and the company's goal of sustainable annual margin expansion of ~50 bps may be challenging to achieve in the current market conditions.
This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.
STERIS (STE) Analyst Forecast & Price Prediction
Start investing in STERIS (STE)
Order type
Buy in
Order amount
Est. shares
0 shares